Efficacy and Safety of mizoribine for MPO-ANCA associated vasculitis; A multicenter randomized controlled trial (Mizoribin for ANCA RPGN Relapse-Prevention study:MARPGN study)
Not Applicable
- Conditions
- MPO-ANCA associated vasculitis
- Registration Number
- JPRN-UMIN000000708
- Lead Sponsor
- Department of Nephrology, Division of Clinical Sciences, Faculty of Medicine, University of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with allergy with Mizoribine Patients with leucocytosis(<3000/mm3) Patients treated with other immunosuppression drug within four weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method BVAS score, time from remmision to relapse, relapse rate
- Secondary Outcome Measures
Name Time Method MPO-ANCA titer, CRP, GFR, amount dose of corticosteroid through the study